Showing results (191-200 of 715) with videos related to

Sort By:
Pageof 72
Cancer|March 29, 2002
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemiaMoshe Talpaz, Ashok Rakhit, Karen Rittweger, et al.
Cancer|March 29, 2002
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemiaJorge Cortes, Deborah Thomas, Adan Rios, et al.
Blood|November 19, 2005
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trialDeepa Sampath, Jorge Cortes, Zeev Estrov, et al.
Blood|September 5, 2009
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upRavin J Garg, Hagop Kantarjian, Susan O'Brien, et al.
American Journal of Hematology|September 25, 2014
Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experienceNaveen Pemmaraju, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|March 22, 2015
Secondary mutations as mediators of resistance to targeted therapy in leukemiaNaval Daver, Jorge Cortes, Farhad Ravandi, et al.
Cancer|February 25, 2003
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.
Cancer|February 29, 2012
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapyHagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, et al.
Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.
Pageof 72